rDNA-DERIVED PRODUCTS' REGULATION BASED ON PRODUCT PROPERTIES
rDNA-DERIVED PRODUCTS' REGULATION BASED ON PRODUCT PROPERTIES and not on production processes should be the basis for regulation, Genex Corp. Senior VP David Jackson told a Senate Environment & Public Works toxic substances subcmte. hearing Sept. 27. Asserting that in regulating rDNA derived products "people have to look at the product and not the process itself," Jackson contended that "it is perfectly possible that the two organisms which result from the modification by two different sets of techniques will be literally identical." In such a case, he said, "it would be very difficult to argue that one organism should be regulated differently from the other simply because a particular set of techniques had been used to construct it." The "vast majority" of rDNA products "fall into categories currently regulated by FDA or EPA [Environmental Protection Agency] or USDA," Jackson said. "In these categories, regulation is generally on the basis of the product's characteristics and the uses to which it is to be put," he said, "and not on the basis of the technology used to produce the product. I see no reason why this present regulatory structure needs to be fundamentally altered for products produced in, containing, or consisting of genetically engineered organisms." Subcmte. Chairman Durenberger (R-Minn.) convened the two-day session, Sept. 25 and 27, to examine the "potential environmental consequences of genetic engineering." Opening the second day of hearings, he commented, "I believe we are correct in approaching the new genetic engineering technologies with prudent caution."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth